Results 61 to 70 of about 52,894 (243)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis

BMC Cancer, 2019
Background Chemotherapy-induced alimentary mucositis (AM) is difficult to prevent and treatment is rarely effective. Recent study have been showed that glucagon-like peptide (GLP)-1 and GLP-2 has protective in chemotherapy-induced AM.
Jung Min Lee, In Kyung Yoo, Jae Min Lee, Seung Han Kim, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Yoon Tae Jeen, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um, Chang Duck Kim   +12 more
doaj   +1 more source

Measurements of 5-FU Plasma Concentrations in Patients with Gastrointestinal Cancer: 5-FU Levels Reflect the 5-FU Dose Applied

Journal of Cancer Therapy, 2012
Introduction: 5-Fluorouracil (5-FU) is the basis of most combination chemotherapies for gastrointestinal tumors. It is generally well tolerated, but side-effects might require dose-adjustment. As adverse events are not specific to the 5-FU component of the chemotherapy-combination, i.e.
Martina Blaschke, Jutta Blumberg, Ulrike Wegner, Martin Nischwitz, Giuliano Ramadori, Silke Cameron   +5 more
openaire   +2 more sources

Incidence of complications following 5-fluorouracil with trabeculectomies

Indian Journal of Ophthalmology, 1993
To investigate the incidence of complications reportedly caused by the use of 5-fluorouracil (5-FU) in glaucoma filtering surgery, we performed trabeculectomy with 5-FU on 57 eyes of 56 patients with advanced glaucoma.
Thomas Ravi, Jacob Aby, Raju Renu, Gieser Stephen, Sen Subir   +4 more
doaj  

RBFOX3 Regulates the Chemosensitivity of Cancer Cells to 5-Fluorouracil via the PI3K/AKT, EMT and Cytochrome-C/Caspase Pathways

Cellular Physiology and Biochemistry, 2018
Background/Aims: RBFOX3, an RNA-binding fox protein, plays an important role in the differentiation of neuronal development, but its role in the chemosensitivity of hepatocellular carcinoma (HCC) to 5-FU is unknown.
Tianze Liu, Xiaojun Wu, Yizhuo Li, Wenjing Lu, Fufu Zheng, Changlin Zhang, Qian Long, Huijuan Qiu, Yixin Li, Qin Ge, Miao Chen, Xinfa Yu, Wangbing Chen, Hongyang Zhang, Wenlin Huang, Meihua Luo, Wuguo Deng, Liren Li   +17 more
doaj   +1 more source

Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles

, 2016
Colon cancer is one of the leading causes of cancer-related death worldwide and the therapy with 5-fluorouracil (5-FU) is mainly limited due to resistance.
BUDILLON, Alfredo, Leone, Alessandra, Maiolino, Sara, Pagliara, Valentina, QUAGLIA, FABIANA, RUSSO, ANNAPINA, RUSSO, GIULIA, Scalia, Giulia, Tatangelo, Fabiana, UNGARO, FRANCESCA   +9 more
core   +1 more source

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer [PDF]

, 2014
Some trial have demonstrated a benefit of adjuvant fluoropirimidine with or without platinum compounds compared with surgery alone. ITACA-S study was designed to evaluate whether a sequential treatment of FOLFIRI [irinotecan plus 5-fluorouracil/folinic ...
Aitini E., Amadori D., Bajetta E., Bidoli P., Boni C., Cantore M., Carlomagno C., Casaretti R., Comella G., Daniele B., Di Bartolomeo M., Di Costanzo F., Di Fabio F., Falcone A., Floriani I., Group Author(s): ITACA-S Intergrp Trial Adjuvant Ch., Labianca R., Landi L., Marchet A., Mini E., Mosconi S., Nitti D., Pinotti G., Pinto C., Poli D., Ravaioli A., Rosati G., Santoro A., Tiberio G.A.M.   +28 more
core   +1 more source

Adherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland—Does Variation Matter?

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Wilms tumour (WT) has excellent event‐free and overall survival (OS). However, small differences exist between countries participating in the same international study. This led us to examine variation in adherence to protocol recommendations as a potential contributing factor.
Suzanne Tugnait, R. Al‐Saadi, A. Lopez‐Cortes, K. Dzhuma, M. Oostveen, J. Brok, S. Irtan, M. Weeks, J. Bate, S. Baker, R. Williams, M. Powis, D. Saunders, O. Olsen, T. Watson, S. Shelmerdine, S. Vaidya, L. Howell, C. Duncan, G. M. Vujanic, C. Stiller, G. P. Balchin, T. Chowdhury, K. Pritchard‐Jones   +23 more
wiley   +1 more source

Results of intraoperative 5-fluorouracil in patients undergoing trabeculectomy - pilot prial

Indian Journal of Ophthalmology, 1996
To study the effect of 5-Fluorouracil (5-FU) in glaucoma filtration surgery, 13 eyes of 12 patients with glaucoma were subjected to trabeculectomy with intraoperative one minute exposure of 50 mg/ml 5-FU. The average age of patients was 36.42 ± 18.
Shelat Binita, Rao B, Vijaya L, Revathi B, Garg Dinesh   +4 more
doaj  

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson, Ingrid Winship, Gary Hammerschlag, Laura Scardamaglia   +3 more
wiley   +1 more source

Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. [PDF]

, 2014
A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584,
Gruber, Harry E, Hiraoka, Kei, Inagaki, Akihito, Iwamoto, Keisuke S, Jolly, Douglas J, Kamijima, Shuichi, Kasahara, Noriyuki, McBride, William H, Micewicz, Ewa, Robbins, Joan M, Takahashi, Masamichi, Valdes, Gilmer   +11 more
core   +2 more sources